Avoiding Medicare: Lilly, Icos and Limiting Part D Exposure
This article was originally published in RPM Report
Executive Summary
Lilly's acquisition of Icos is a big bet on the future of private pay medicines. Lilly is paying $2.1 billion for sole rights to Cialis, in part because the company is happy to have a brand that operates outside of the influence of managed care gatekeepers in the US.
You may also be interested in...
Can You Hear That Whistle Blow? Sales Force Reductions Come with Risks
Pfizer's big sales force cuts mark the beginning of a disarmament in sales infrastructure across the pharmaceutical industry. That means a lot of sales reps will be out of work-and looking for payback.
Can You Hear That Whistle Blow? Sales Force Reductions Come with Risks
Pfizer's big sales force cuts mark the beginning of a disarmament in sales infrastructure across the pharmaceutical industry. That means a lot of sales reps will be out of work-and looking for payback.
A Cold Shower For Viagra: How Congress Can Chill A Market
Pfizer, Lilly and the other marketers of drugs for erectile dysfunction are kicked out of Medicare and Medicaid. Viagra and the other brands may be the first victims of the backlash against DTC advertising. They are also a case study in how Congress can--and well--make mischief under the Medicare program.